The SMAD pathway is one of the central information conduits in animal cells. It is switched on by more than thirty ligands of the TGF-β superfamily, which bind to serine/threonine kinase receptors at the cell surface. When a ligand latches on, type II receptors phosphorylate and activate type I receptors, which in turn phosphorylate receptor-associated SMAD proteins. These activated R-SMADs partner with the common mediator SMAD4, travel into the nucleus and steer the transcription of target genes. The pathway splits into two major branches: the TGF-β branch, carried by ligands such as TGF-β, Activins and GDFs through the type I receptors ALK4 and ALK5 into SMAD2 and SMAD3, and the BMP branch, carried by BMP ligands through ALK1, ALK2 and ALK3 into SMAD1, SMAD5 and SMAD9. In endothelial cells this division of labor is beautifully choreographed during angiogenesis. Tip cells at the leading edge of a sprouting vessel rely on SMAD1/5/9 activation by BMP2, BMP6 and BMP7 to navigate, while stalk cells behind them depend on SMAD2/3 signaling through TGF-β to proliferate and form a proper lumen. In mature vessels, BMP9 and BMP10 keep the endothelium quiescent through SMAD1/5/9.

When this balance breaks, human disease follows. Mutations in ALK1, the BMP9 receptor, or its co-receptor endoglin weaken SMAD1/5/9 signaling and cause hereditary hemorrhagic telangiectasia, a disorder marked by fragile arteriovenous malformations and recurrent bleeding. Conversely, mutations in BMPR2 that heighten SMAD2/3 activity contribute to pulmonary arterial hypertension, in which vessels narrow and remodel abnormally. Understanding how individual cells weigh pro- and antiangiogenic inputs is therefore not just a question of basic biology but a prerequisite for new therapies. Yet most of what we know about SMAD signaling comes from population averages, which can mask the striking variability that individual cells display.

To see signaling cell by cell, the team built stable reporter lines in EA.hy926 cells, a widely used model of human vascular endothelium derived from fusing primary umbilical vein cells with a lung carcinoma line. They fused the cDNA of SMAD1 to the yellow fluorescent protein mVenus under a constitutive ubiquitin C promoter, and co-expressed a histone H2B-CFP nuclear marker so that automated image analysis could segment and track every nucleus over time. Parallel reporters were generated for SMAD5 and SMAD9. Western blotting confirmed that the tagged proteins were phosphorylated with the same kinetics as their endogenous counterparts after BMP9 stimulation, peaking around 1.5 hours, and RT-qPCR showed that key target genes such as Endothelin 1 and ID2 were induced normally, indicating that the reporters did not distort the pathway they were meant to observe.

Time-lapse microscopy at ten-minute intervals over sixteen hours then delivered the first surprise: enormous cell-to-cell heterogeneity. After BMP9 addition, essentially all cells pushed SMAD1 into the nucleus within about an hour, but what happened next differed dramatically. Some cells settled into stable signaling, while others repeatedly shuttled SMAD1 back and forth in pulsatile waves. The population median showed a sharp peak at roughly 1.5 hours followed by a gradual return to baseline, and even a medium-only control, containing no added ligand, elicited a small translocation peak, revealing exquisite sensitivity to trace amounts of BMP-family ligands left in the serum. Dose-response experiments showed that peak SMAD1 translocation saturated at about 0.375 nanograms per milliliter of BMP9, with a half-maximal effective concentration of just 0.06 nanograms per milliliter. Higher doses produced sustained nuclear occupancy and delayed adaptation, consistent with the idea that signaling duration is governed largely by ligand depletion as receptors internalize and degrade their cargo.

The three R-SMADs of the BMP branch, often assumed to be interchangeable, turned out to differ quantitatively in revealing ways. SMAD5 required the highest ligand concentrations to respond, showing the largest EC50 of the three, and failed to react even to the residual ligand in the medium-only control, suggesting it cannot compensate at low signal doses. SMAD9, by contrast, returned to the cytoplasm more slowly than SMAD1 or SMAD5 once the ALK1 inhibitor K02288 was applied, hinting that its prolonged nuclear retention may serve processes requiring sustained gene expression, such as pulmonary vascular remodeling. Pharmacological validation confirmed that BMP9 signaling runs through ALK1, with an IC50 of 192 nanomolar for SMAD1, and lower values of 47 and 107 nanomolar for SMAD5 and SMAD9 respectively.

The pivotal discovery came when the team screened a panel of TGF-β superfamily ligands. Despite the presence of receptors for BMP2, BMP6 and BMP7, only BMP9 and BMP10 drove robust nuclear translocation of SMAD1, SMAD5 and SMAD9 in these endothelial cells, even at very high ligand concentrations. Suspecting an intracellular brake rather than an extracellular one, the researchers focused on FKBP12, the FK506-binding protein known to dock onto the glycine-serine-rich region of type I receptors and physically block their phosphorylation by type II receptors. FKBP12 was highly expressed in the cells. To remove it cleanly, the team used a proteolysis-targeting chimera, a bifunctional molecule that recruits the von Hippel-Lindau ubiquitin ligase to FKBP12 and triggers its degradation. Western blots confirmed dose- and time-dependent FKBP12 loss, and the consequences were striking: with FKBP12 gone, BMP7 and Activin A, ligands that had previously been mute, suddenly provoked strong SMAD1 activation through ALK2, while the response to BMP9 and BMP10 remained almost unchanged.

FKBP12 did more than simply unlock a second receptor. Using a dual reporter line expressing YFP-SMAD1 and mCherry-SMAD2 simultaneously, the researchers showed that BMP7 normally produces a weak SMAD1 response and a robust SMAD2 response. Degrading FKBP12 shifted the balance: SMAD1 translocation rose, particularly at high BMP7 concentrations, while the SMAD2 response fell. Co-stimulation experiments with BMP9 and TGF-β, which engage distinct receptor complexes, produced no mutual attenuation, ruling out feedback loops or pathway competition as the explanation. Instead, the data point to limited shared receptor availability and differential receptor complex composition. The authors propose that BMP7-induced SMAD2 activation depends on heterodimeric ALK2/ALK4 complexes, whereas SMAD1 activation after FKBP12 removal relies on ALK2 homodimers, and that Activin A can additionally engage ALK4 homodimers. In this model, FKBP12 does not merely silence receptors; it actively determines which receptor assemblies form and therefore which branch of the pathway a given ligand will engage.

These signaling shifts translated into real cellular behavior. The SMAD1/5/9 target gene DLL4 dropped sharply after BMP9 treatment and stayed flat when only SMAD2/3 was engaged, but FKBP12 degradation made BMP7 a potent DLL4 repressor as well. The gene ID2, regulated by both branches, showed additive induction when both pathways fired. Over 48 hours of single-cell tracking, BMP9 significantly boosted endothelial motility, an effect abolished by ALK1 inhibition, while BMP7 increased motility more modestly, and combining BMP7 with FKBP12 degradation produced an additive enhancement that ALK4/5 inhibition could curtail. The findings suggest that SMAD1/5/9 and SMAD2/3 cooperate rather than compete in shaping endothelial phenotypes, with FKBP12 acting as a fine-tuning dial. Therapeutically, the implications are tantalizing. The immunosuppressant FK506, known clinically as tacrolimus, displaces FKBP12 from receptor complexes and is already being piloted to reduce bleeding in hereditary hemorrhagic telangiectasia, while FKBP12-specific PROTACs could offer a more selective route that spares the immune system. The authors caution that EA.hy926 cells are a hybrid model and that the receptor-complex model rests on pharmacological inference, so validation in primary endothelial cells and in vivo disease models remains the essential next step. Even so, the study reframes FKBP12 from a passive receptor cap into an active architect of ligand-specific signaling, one that cells may exploit, and clinicians may one day target, to restore the delicate balance their vessels depend on.

Subject of Research: FKBP12-dependent regulation of ligand-specific SMAD signaling in living endothelial cells

Article Title: FKBP12 determines ligand-specific SMAD signaling in individual living endothelial cells

Article References: Huang, Z., Lenhardt, S., Snyder, P., Bulldan, A., Hausch, F., & Loewer, A. (2026). FKBP12 determines ligand-specific SMAD signaling in individual living endothelial cells. iScience, 29(10), Article 117728. https://doi.org/10.1016/j.isci.2026.117728

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117728

Keywords: SMAD signaling, FKBP12, endothelial cells, BMP9, TGF-β, ALK1, ALK2, PROTAC, live-cell microscopy, angiogenesis, hereditary hemorrhagic telangiectasia, pulmonary arterial hypertension

HHT is a genetic disorder characterized by abnormal blood vessel formation, leading to excessive bleeding and related complications. This condition results from mutations in components of the TGF-beta signaling pathway, notably in the endoglin and ALK1 genes. However, the interplay with juvenile polyposis due to SMAD4 mutation adds an intriguing layer of complexity to our understanding of vascular pathologies. The SMAD4 gene, vital for cellular signaling, is implicated in various developmental processes, and its mutation leads to a serious predisposition to both malignancies and vascular anomalies.

The case study under discussion highlights a patient presenting unusual symptoms that were ultimately linked to an acute aortic dissection. This life-threatening condition arises when a tear occurs in the aortic wall, allowing blood to flow between layers of the vessel. In this patient, the intertwining of HHT and juvenile polyposis, primarily due to the SMAD4 mutation, created a rare clinical scenario that posed numerous questions regarding diagnosis and treatment.

Researchers delved into the genetic landscape of the patient, revealing the presence of the SMAD4 mutation, which not only is pivotal in the context of polyposis but also critically influences angiogenesis—the process of new blood vessel formation. Understanding how SMAD4 dysfunction contributes to vascular instability aids in unraveling the risks associated with HHT and related vascular disorders. Consequently, this case not only underscores the severity of acute aortic dissection but also highlights the need for comprehensive genetic screening in patients presenting with similar profiles.

The pathophysiology of acute aortic dissection in this context can be partially attributed to the fragility of vascular structures resulting from mutant SMAD4 signaling pathways. Research indicates that disturbances in these pathways can lead to the abnormal proliferation of vascular smooth muscle cells, increasing susceptibility to dissection. This insight into the molecular mechanisms emphasizes the importance of aware clinical vigilance in patients with inherited syndromes like HHT.

Moreover, the interdisciplinary nature of this study illustrates the growing trend of integrating genetic research with clinical practice. It advocates for a multi-faceted approach in managing complex conditions, where understanding the genetic underpinnings becomes essential for effective intervention strategies. Genetic testing and counseling are becoming vital components of patient management, allowing for early detection and management of potential complications linked to these inherited syndromes.

In this case analysis, the researchers underscore the critical role of early diagnostic imaging. Patients with familial background and symptoms indicative of HHT or polyposis should undergo thorough evaluation with advanced imaging techniques such as echocardiography or CT angiography. In this specific patient, early intervention facilitated timely surgical manipulation, yet it simultaneously illuminated the pressing need for guidelines that consider the specific risk factors associated with combined genetic disorders.

The findings reiterate the importance of maintaining a high index of suspicion for atypical presentations of common conditions, particularly in patients with known genetic vulnerabilities. Clinicians are urged to adopt a more holistic view of patient history, emphasizing genetic predispositions that may complicate usual diagnostic and treatment algorithms.

As the medical community continues to piece together the nuances of genetic diseases, this research serves as a pivotal reminder of the intricate relationships between various conditions. The association of HHT with juvenile polyposis via the SMAD4 mutation resonates profoundly in a slowly evolving understanding of how genetic nuances influence vascular health.

Furthermore, these insights not only pave the way for better management strategies but also stimulate further research into targeted therapies. As our grasp of genetics advances, there exists an opportunity to develop specific pharmacological interventions aimed at mitigating the risks posed by such mutations, ultimately transforming patient outcomes.

The complexities surrounding acute aortic dissection in the context of genetic predispositions such as HHT and juvenile polyposis challenge conventional therapeutic paradigms. Hence, the study lays groundwork for future inquiries that could redefine clinical pathways in managing such challenging cases.

This research is not just a glimpse into a rare clinical occurrence; it resonates with the larger discourse in medicine concerning genetics, vascular biology, and integrated care. As researchers further investigate the multifaceted nature of these genetic disorders, we are reminded of the continuous and evolving dialogue between genetics and clinical practice—one that is essential for advancing our understanding and treatment of complex health issues.

In conclusion, the study highlights a pressing clinical issue within a broader context of genetic illness, urging medical professionals to stay ahead of the curve in genetic screening and specialized management. The interconnection between HHT, juvenile polyposis, and acute aortic dissection serves as a compelling case study, paving the way for future research, enhanced understanding, and improved patient care in the landscape of hereditary disorders.

Subject of Research: The association of acute aortic dissection with hereditary hemorrhagic telangiectasia and juvenile polyposis due to SMAD4 mutation.

Article Title: RE: acute aortic dissection in a patient with hereditary hemorrhagic telangiectasia associated with juvenile polyposis due to SMAD4 mutation.

Article References: Harahsheh, E.Y., Bcharah, G., Asif, M.B. et al. RE: acute aortic dissection in a patient with hereditary hemorrhagic telangiectasia associated with juvenile polyposis due to SMAD4 mutation. Angiogenesis 28, 41 (2025). https://doi.org/10.1007/s10456-025-09999-z

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10456-025-09999-z

Keywords: Hereditary hemorrhagic telangiectasia, juvenile polyposis, SMAD4 mutation, acute aortic dissection, genetics, vascular biology.